Bladder Disease


Diseases of the bladder comprise a wide variety of conditions affecting millions of patients worldwide, including over 50 million in the United States alone.

Major bladder diseases include bladder cancer, voiding dysfunction, urinary tract infections as well as renal

and urinary stones.

These diseases affect patients of all ages and have profound impact on their quality of life and overall health.




    • Bladder cancer is where a growth of abnormal tissue, known as a tumour, develops in the bladder lining. In some cases,

        the tumour spreads into the bladder muscle.


    • Bladder cancer ranks as the ninth most frequently-diagnosed cancer worldwide, with the highest incidence rates observed in men in Southern and Western

       Europe, North America, as well in certain countries in Northern Africa or Western Asia [2].


    • 430 000 new cases of bladder cancer were diagnosed in 2012 [1].


    • Bladder cancer ranks 13th in terms of deaths ranks [2].


    • The estimated U.S. national expenditure on bladder cancer was $4.6 billion in 2017 [3].


    Bladder cancer can be divided into 3 categories [4]:

    If the cancerous cells are contained inside the lining of the bladder, doctors describe it as non-muscle-invasive bladder cancer. This is the most common type of bladder cancer. Most people don't die as a result of this type of bladder cancer. Treatment is directed at reducing recurrences and preventing progression to a more advanced stage.


    When the cancerous cells spread beyond the lining, into the surrounding bladder muscle, it's referred to as muscle-invasive bladder cancer (MIBC).

    This is less common, but has a higher chance of spreading to other parts of the body. The goal of therapy is to determine whether the bladder should be removed or if it can be preserved without compromising survival, and to determine whether the primary lesion can be managed independently or if patients are

    at high risk for distant spread requiring systemic approaches to improve the likelihood of cure.


    If bladder cancer has spread to other parts of the body, it's known as advanced or metastatic bladder cancer. The critical concern for the third group is how to prolong quantity and maintain quality of life.


    Biomodics is advancing local drug delivery for the treatment of muscle invasive bladder cancer (MIBC). This program continuously administers approved carcinogenic agents for multiple weeks. We believe that our solution has the potential to harness both direct antitumor and immuno-oncologic activity without meaningful systemic drug exposure, yielding a powerful therapy and mitigating systemic side-effects.



    1. GLOBOCAN 2012 v1.0, cancer incidence and mortality worldwide: IARC CancerBase No. 11. International Agency for Research on Cancer Web site. http://globocan.iarc.fr

    2. Antoni, S., et al., Eur Uro 2017, 17, 96- 108

    4. Spiess, P.E., et al., J Natl Compr Canc Netw 2017;15:1240-1267




    Approximately 25% of patients who are admitted to a hospital will have an indwelling catheter at some point of their stay [1].


    7% of nursing home residents are managed by long term catheterization [1].


    At least 6.25% of patients develop CAUTI while having an indwelling catheter [2].


    100% of patients develop a bacterial infection within 30 days of catheterization [3].


    CAUTI accounts for approximately 40% of all hospital-acquired infections [4-6].


    Treatment is extremely difficult whilst the catheter remains in place [7].


    Bacteria causing CAUTI: Staphylococcus epidermidis, Escherichia coli and Enterococcus faecalis.


    3.6% of the CAUTI will develop into a bloodstream infection [8].


    Bloodstream infections are life threatening with a mortality rate of 12-25%.


    The global market for Foley catheters is 100 million units (25 million in US).


    In the US alone, 600,000 patients develop CAUTI each year.


    The combined U.S. and European urology device market was valued at almost US$4.7 billion in 2013.

        According to the World Health Organization (WHO) estimates, over 200 million people are suffering from one or the other bladder

        control problems that essentially require urinary catheterization. According to the National Health Service (NHS) of the U.K., approximately

        3 million to 6 million people were suffering from some degree of urinary incontinence in the U.K. in 2013.


    Biomodics is upgrading urinary catheters for targeted drug delivery locally in the bladder. Antimicrobial agents are delivered directly to the bladder through the semipermeable balloon in the tip of the catheter. We believe that this new strategy improve stability, reduce dosage, increase efficacy and bioavailability, reduce cost, whilst decreasing time-to-market and improving patient compliance.



    1.Newman, D.K., Journal of Wound Ostomy Continence Nursing, 2007, 34, 655 – 661.

    2.Rebmann T., Greene, L.R., American Journal of Infection Control, 2010, 38, 644 – 646.

    3.Winson, L., British Journal of Nursing, 1997, 6, 1229 – 1252.

    4.Kunin, C.M., New England Journal of Medicine, 1988, 319, 365 – 366.

    5.Sullivan, L.L., et al., ASEE Annual Conference Proceedings, 1995, 2, 2168 – 2172.

    6.Reiche, T., et al., British Journal of Urology International, 2000, 85, 54 – 59.

    7.Denstedt, J.D., Wollin T.A., Reid G., Journal of Endourology, 1998, 12, 493 – 500.

    8.Saint, S., American Journal of Infection Control, 2000, 28, 68 – 75.




    15% of men and 25% of women experience a frequent feeling of needing to urinate to a degree that it negatively affects a person’s life. The economic costs of overactive bladder were estimated in the United States at 12.6 billion USD and 4.2 billion Euro in 2000 [1].


    Overactive bladder (OAB) can result from an underlying neurologic injury (neurogenic detrusor overactivity, or NDO) or from unclear etiology (idiopathic overactive bladder, or iOAB).


    In addition to significant loss of patient productivity, billions of dollars are spent annually to treat OAB patients with medications, surgical treatments

    and behavioral modifications [2].


    Biomodics is developing a continuous local therapy for the management of OAB using approved agents. By dosing this drug directly to the bladder through the semipermeable balloon for an extended period, we believe that our solution has the potential to offer substantially improved efficacy, while minimizing

    bothersome systemic side effects seen with oral administration of these types of agents. We believe this has the potential to be the best available therapy for patients unsatisfied with oral treatments.



    1. Abrams, Paul (2011). Overactive bladder syndrome and urinary incontinence. Oxford: Oxford University Press. pp. 7-8, ISBN [978-0-19-959939-4]

    2. Ganz ML., Urology, 2010, 75(3), 526-532



    Biomodics has invented and developed the ideal solution to the problem of bladder diseases. For the first time it is possible to administer the drug level in the bladder. Instead of coating the catheter, the liquid used to inflate the balloon is spiked with active pharmaceutical agents. By using a unique patented combination of materials, the balloon becomes semipermeable and allows the active agents to continuously pass through the balloon at a constant rate

    for as long as the user desires.


    Biomodics’ Foley catheter enables transport of drugs through the balloon material. The key is the transformation of the balloon material into a

    semi-permeable membrane. Supercritical carbon dioxide (scCO2) is used as an auxiliary solvent to swell the balloon material (typically made of silicone rubber or polyurethane). In the swollen state, it is possible to impregnate a hydrogel into the base material of the balloon. The hydrogel constitutes a second interconnected network throughout the balloon material. This novel hybrid material called IPN allows the free diffusion of drugs through the balloon.

    Interpenetrating polymer networks (IPNs) are defined as a polymer blend comprising two or more networks, which are at least partially interlaced on a molecular scale but not covalently bonded to each other and cannot be separated unless chemical bonds are broken.  An IPN is made when a cross-linked polymer (the substrate material) is swollen with a different monomer (the guest monomer), then the monomer is polymerized and cross-linked.



Vascular Disease


Cardiovascular disease is the leading cause of death and disease globally causing over 17 million people dying each year. 1–6% of vascular graft procedures are infected. The costs associated with one infection are estimated at US$40,000. Mortality ranges between 13% and 58%, and the amputation rate in survivors varies between 8% and 52%. Immediate occlusive complications are seen in up to 18% of patients. Restenosis occurs around 10 years after the procedure. We can prevent these problems.



Overall, raised cholesterol is estimated to cause 2.6 million deaths (4.5% of total) and 29.7 million disability adjusted life years (DALYS), or 2.0% of total DALYS. Raised cholesterol increases the risks of heart disease and stroke. Globally, a third of ischaemic heart disease is attributable to high cholesterol. Raised total cholesterol is a major cause of disease burden in both the developed and developing world as a risk factor for Ischemic heart disease and stroke.

In 2008 the global prevalence of raised total cholesterol among adults (≥ 5.0 mmol/l) was 39% (37% for males and 40% for females).



In 2016, 39% of women and 39% of men aged 18 and over were overweight [WHO]. Overweight and obesity are major risk factors for a number of chronic diseases, including diabetes, cardiovascular diseases and cancer.

Once considered a problem only in high income countries, overweight and obesity are now dramatically on

the rise in low- and middle-income countries, particularly in urban settings [WHO]


Worldwide obesity has nearly tripled since 1975. In 2016, more than 1.9 billion adults, 18 years and older, were overweight. Of these over 650 million were obese. 39% of adults aged 18 years and over were overweight in 2016, and 13% were obese. Most of the world's population live in countries where overweight and obesity kills more people than underweight. 41 million children under the age of 5 were overweight or obese in 2016. Over 340 million children and adolescents aged 5-19 were overweight or obese in 2016. Obesity is preventable.



Diabetes is the leading risk factor for kidney disease and the number one cause of kidney failure. More than 29 million Americans have diabetes, and almost half of all kidney failure cases are caused by diabetes.




    Your kidneys filter wastes and excess fluids from your blood, which are then excreted in your urine. When your kidneys lose their filtering capabilities, dangerous levels of fluid, electrolytes and wastes can build up in your body.


    In most cases, kidney failure is caused by other health problems that have done permanent damage (harm) to your kidneys little by little, over time.


    Kidney failure, also called end-stage renal disease (ESRD), is the last stage of CKD. When your kidneys fail, it means they have stopped working well enough for you to survive without dialysis or a kidney transplant.


    Dialysis is a technique used to remove waste products, such as urea and creatinine, from the blood due to inappropriate functioning of kidney and is usually required for people suffering from chronic renal failure. A plastic tube (AV-graft) is connecting an artery to a vein, creating an access point for repeated dialysis treatment. This procedure is required during the treatment of end-stage renal disease and kidney transplant. In this procedure, the blood is purified, excess fluid and toxins are removed, and electrolyte balance is restored in the blood.


    Dialysis Market was valued at $86,621 million in 2016, and is estimated to reach $118,512 million by 2023, registering a CAGR of 4.5% from 2017 to 2023 [1]. 30 million people in the United States are living with chronic kidney disease (CKD). Over 500,000 patients diagnosed with end-stage renal disease.


    AV-graft failure occurs due to stenosis (narrowing in a blood vessel and other tubular structures), thrombosis (blood clotting) and infections. Stenosis is due to intimal hyperplasia and fibrosis [2].

    When stenotic lesions (primarily neointimal hyperplasia) develop in association with an AV-graft, it often results in thrombosis. More than 90 percent of thrombosed AV-grafts have a stenotic lesion, suggesting that such an anatomic abnormality is required for AV-graft thrombosis. The majority of AV-grafts develop stenosis or thrombosis. Among 649 patients with new AV-grafts enrolled in the Dialysis Access Consortium (DAC) Study, 77 percent developed stenosis or thrombosis within the first year [3]. Similarly, among 201 patients with a new AV-graft enrolled in the Fish Oil Inhibition of Stenosis in Hemodialysis Grafts (FISH) Study, 62 percent developed stenosis or thrombosis within one year [4].


    Biomodics is developing an AV-graft that prevents stenosis, thrombosis and infections. By a unique patented combination of novel biomimicking materials and targeted local drug delivery the body does not recognize nor reject the AV-graft as an artificial material.



        Accessed September 12, 2018.

    2. Chan AW, Chi YW. Venous stenosis. In: Bhatt DL, editor. Guide to Peripheral and Cerebrovascular Intervention. London: Remedica; 2004. Available from:

    3. Dixon BS, Beck GJ, Vazquez MA, et al. Effect of dipyridamole plus aspirin on hemodialysis graft patency. N Engl J Med 2009; 360:2191.

    4. Lok CE, Moist L, Hemmelgarn BR, et al. Effect of fish oil supplementation on graft patency and cardiovascular events among patients with new synthetic arteriovenous hemodialysis

        grafts: a randomized controlled trial. JAMA 2012; 307:1809.



    Coronary artery disease develops when the major blood vessels that supply your heart with blood, oxygen and nutrients (coronary arteries) become

    damaged or diseased [1].


    The damage may be caused by smoking, high blood pressure, high cholesterol, diabetes and sedentary lifestyle.


    Cholesterol-containing deposits (plaque) in your arteries and inflammation are usually to blame for coronary artery disease. When plaque builds up, it narrows your coronary arteries, decreasing blood flow to your heart. Eventually, the decreased blood flow may cause chest pain (angina), shortness of breath, or other coronary artery disease signs and symptoms. A complete blockage can cause a heart attack.


    Because coronary artery disease often develops over decades, you might not notice a problem until you have a significant blockage or a heart attack. But there's plenty you can do to prevent and treat coronary artery disease. A healthy lifestyle can make a big impact.


    In 2015 CAD affected 110 million people worldwide and resulted in 8.9 million deaths [2,3].

    It makes up 15.9% of all deaths making it the most common cause of death globally [3].

    The risk of death from CAD for a given age has decreased between 1980 and 2010, especially in developed countries [4].

    The number of cases of CAD for a given age has also decreased between 1990 and 2010 [5].

    In the United States in 2010 about 20% of those over 65 had CAD, while it was present in 7% of those 45 to 64, and 1.3% of those 18 to 45 [6].

    Rates are higher among men than women of a given age [6].


    Coronary artery bypass graft (CABG) surgery is a surgical procedure to restore normal blood flow to an obstructed coronary artery.

    A normal coronary artery transports blood to and from the heart muscle itself, not through the main circulatory system.


    CABG is one of the most common procedures performed during U.S. hospital stays; it accounted for 1.4% of all operating room procedures

    performed in 2011 [7]. Between 2001 and 2011, however, its volume decreased by 46%, from 395,000 operating procedures performed in 2001 to 213,700 procedures in 2011 [8].


    Between 2000 and 2012, the number of CABG procedures carried out decreased across the majority of OECD countries. However, there remained substantial variation in the rate of procedures, with the U.S. carrying out four times as many CABG operations per 100,000 people as Spain [9]. These differences do not appear to be closely related to the incidence of heart disease, but may be due to variation in financial resources, capacity, treatment protocols and reporting methods [10].


    Due to the small inner diameter of the vessels artificial grafts fail due to stenosis. Therefore bypass grafts are harvested from the patient – frequent vessels are the internal thoracic arteries, radial arteries and saphenous veins. Harvesting the patient’s own veins increases the risk for complications. Biomodics is developing the first artificial graft that prevent stenosis even with small vessels sizes, which is a brilliant upgrade for CABG.



    2. GBD 2015 Disease and Injury Incidence and Prevalence, Collaborators. (8 October 2016). "Global, regional, and national incidence, prevalence, and years lived with disability for 310

        diseases and injuries, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015". Lancet. 388 (10053): 1545–1602. doi:10.1016/S0140-6736(16)31678-6.

    3. GBD 2015 Mortality and Causes of Death, Collaborators. (8 October 2016). "Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of

        death, 1980–2015: a systematic analysis for the Global Burden of Disease Study 2015". Lancet. 388 (10053): 1459–1544. doi:10.1016/S0140-6736(16)31012-1.

    4. Moran, AE; Forouzanfar, MH; Roth, GA; Mensah, GA; Ezzati, M; Murray, CJ; Naghavi, M (8 April 2014).  "Temporal trends in ischemic heart disease mortality in 21 world regions, 1980 to

        2010: the Global Burden of Disease 2010 study". Circulation. 129 (14): 1483–92. doi:10.1161/circulationaha.113.004042.

    5. Moran, AE; Forouzanfar, MH; Roth, GA; Mensah, GA; Ezzati, M; Flaxman, A; Murray, CJ; Naghavi, M (8 April 2014). "The global burden of ischemic heart disease in 1990 and 2010: the Global

        Burden of Disease 2010 study". Circulation. 129 (14): 1493–501. doi:10.1161/circulationaha.113.004046.

    6. Centers for Disease Control and Prevention, (CDC) (14 October 2011). "Prevalence of coronary heart disease—United States, 2006–2010". MMWR. Morbidity and Mortality Weekly Report.

        60 (40): 1377–81.

    7.Weiss AJ, Elixhauser A, Andrews RM (February 2014). "Characteristics of Operating Room Procedures in U.S. Hospitals, 2011". HCUP Statistical Brief #170. Rockville, MD: Agency for

       Healthcare Research and Quality.

    8. Weiss AJ, Elixhauser A (March 2014). "Trends in Operating Room Procedures in U.S. Hospitals, 2001—2011". HCUP Statistical Brief #171. Rockville, MD: Agency for Healthcare Research

         and Quality.

    9. "Indicator: International comparisons of surgical procedures". QualityWatch. Nuffield Trust & Health Foundation. Retrieved 5 May 2015.

    10. Lafortune, Gaetan. "Comparing activities and performance of the hospital sector in Europe: how many surgical procedures performed as inpatient and day cases?" (PDF). OECD. OECD.

          Retrieved 5 May 2015.




    Peripheral arterial disease (PAD) is a blood circulation disorder that causes the blood vessels outside of your heart and brain to narrow, block, or spasm.

    It is most common in the arteries of the legs and is increasingly recognized as a health burden worldwide. In the case of PAD, blood vessels narrow, due to deposition of plague inside the arteries, which decreases the blood flow (Atherosclerosis). Approximately 12% to 20% of people over age of 60 develop PAD.

    The main risk factors are: smoking, high blood pressure, obesity, high cholesterol, aging and diabetes. Approximately 8.5 million individuals in the US have peripheral arterial disease [1].


    • In 2015 about 155 million people had PAD worldwide.[2]

    • In the developed world it affects about 5.3% of 45 to 50 years olds and 18.6% of 85- to 90-year-olds.[3]

    • In the developing world it affects 4.6% of people between the ages of 45 to 50 and 15% of people between the ages of 85 to 90.[3]

    • In the developed world PAD is equally common among men and women while in the developing world women are more commonly affected.[3]

    • In 2015 PAD resulted in about 52,500 deaths up from 16,000 deaths in 1990.[4,5]


    The most common symptoms of PAD involving the lower extremities are cramping, pain or tiredness in the leg or hip muscles while walking or climbing stairs. Typically, this pain goes away with rest and returns when you walk again.


    In early stages PAD can be treated with lifestyle changes and medications, however in latter stages, it may lead to stroke, heart attack, or lower limb amputation.

    If PAD is not treated in early stages, angioplasty (insertion of a catheter or long tube into an artery) or vascular bypass surgery is required.


    PAD treatment requires smaller diameter (<6mm) graft. However, due to graft failure, primarily from intimal hyperplasia, no vascular graft is on the market.

    This opens a niche for a separate product category, which is yet underserved.


    Biomodics develops a biomimicking artificial vascular graft that stays open even with small diameter vessels.



    2.  GBD 2015 Disease and Injury Incidence and Prevalence, Collaborators. (8 October 2016). "Global, regional, and national incidence, prevalence, and years lived with disability for 310

         diseases and injuries, 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015". Lancet. 388 (10053): 1545-1602. doi:10.1016/S0140-6736(16)31678-6.

    3. Fowkes, FG; Rudan, D; Rudan, I; Aboyans, V; Denenberg, JO; McDermott, MM; Norman, PE; Sampson, UK; Williams, LJ; Mensah, GA; Criqui, MH (19 October 2013). "Comparison of global

        estimates of prevalence and risk factors for peripheral artery disease in 2000 and 2010: a systematic review and analysis". Lancet. 382 (9901): 1329–40.


    4. GBD 2015 Mortality and Causes of Death, Collaborators. (8 October 2016). "Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes

        of death, 1980-2015: a systematic analysis for the Global Burden of Disease Study 2015". Lancet. 388 (10053): 1459–1544. doi:10.1016/s0140-6736(16)31012-1.

    5.  GBD 2013 Mortality and Causes of Death, Collaborators (17 December 2014). "Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of

         death, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013". Lancet. 385 (9963): 117–71. doi:10.1016/S0140-6736(14)61682-2.






    Vascular grafts are medical devices that are used for restoring the blood flow in a human body. Grafts are flexible tubes, typically made from materials, such as Teflon and Dacron, which are surgically attached outside of a blood vessel.


    The market for vascular grafts is growing. It was valued at 1,845.9 € million in 2014 and is expected to witness lucrative growth over the upcoming years, due to prevalence of diabetes, unhealthy lifestyle and cardio diseases. The market is expected to reach 3425 € million by 2022.


    The ideal vascular graft has the appropriate size to match the host vessels, allows for rapid healing, ease of handling, exhibits increased porosity, resistance to infection, low thrombogenity and is low cost. Our solution fulfills all these criteria.


    Our solution is unique compared to all existing solutions. With our patented dry chemical technology we are able to impregnate thrombosis-resistant polymers into a complex bulk silicone or PU material. This post-treatment can be applied to existing devices of any shape. The resulting interpenetrating polymer network (IPN) integrates hemocompatible properties into the silicone bulk material, which has never been achieved before. The result is highly beneficial mechanical and hemo-compatible properties in one material which does not decompose In Vivo. A further add-on option is the opportunity to load the impregnated hydrogel with active pharmaceutical ingredients (anti-thrombotic/anti-microbial) for long term release which can be triggered. This option can also be used for impregnating biosensors into the material of the medical device. In summary this can lead to products which are less invasive, better integrated and safe because they can change colour based on risk factors such as infection.



Drug Delivery


Biomodics use carbon dioxide (CO2) to develop drug delivery systems, specialty polymers, nanoparticles

and sterilization of fragile biological components.


Biomodics enables targeting and dosing of drugs to treat CNS, pain, infections and cancer.


Biomodics technologies are compatible with medical devices for local treatments.


Biomodics migrates new and existing drugs into combination products.





    About wound healing



       14 billion dollar global industry, US 2 billion dollar market, with a CAGR of 10% between 2010 and 2017. 20% US population > 65 are affected in 2020. 8%

       US diabetic, 15% develop a diabetic foot ulcer.


    What is the issue with current solutions

       The quality of healing is too low for a range of wound care products. Therefore, it is necessary to improve a range of aspects such as infection management

       and diagnostics.


    Potential in market

       Biomodics has developed simple low-cost sensors for wound site diagnostics. They are integrated with a dressing controlling evaporation and infection

       management. This will address the future burden of advanced wound care management within segments such as diabetic foot ulcer.



    About contact lenses

       Contact lenses for eye diseases have not yet been a huge impact. However, diagnostics and treatment are strong needs in a growing market. According to

       Wilmer Ophthalmological Institute, US, one of the major diseases is glaucoma. 60.5 Mn people across the globe are affected with glaucoma and the number is

       expected to increase to 79.6 Mn by 2020.



       Controlling drug delivery and diagnosing the eye disease is key to manage eye diseases.


    What is the issue with current solutions

       Upcoming solutions may be too expensive and complicated while performance is inadequate.


    Potential in market

       Biomodics contact lens design relies on high drug loading capacity sustained drug delivery and low cost non-invasive integrated sensors. Therefore, the

       components to address the mass market are available.



    About nerve block catheter

       Nerve block catheters are used to block pain due to surgery. It functions in close proximity to a nerve.



       Orthopaedic surgery often results in pain which cannot be managed efficiently.


    What is the issue with current solutions

       Existing nerve block catheters dislocates and may cause nerve damage. Other pain treatments often prove insufficient.


    Potential in market

       Biomodics’ solution includes a balloon in the tip to prevent dislocation.

       In this way patients do not need to rush back to hospitals for repeated and costly pain procedures.




    CO2 under pressure is optimal for producing various well defined sizes of particles which are ultra clean for pharmaceutical purposes.




    Sterilizing fragile biological components can be a major challenge.

    CO2 technology can be used without destroying the functionality of such components



Biomodics – innovating to improve biocompatibility


Biomodics is an independent Danish service and technology provider to the life science industry. With a background in the NKT technology cluster Biomodics ApS was founded in 2010 and holds the patent

portfolio for supercritical CO2, interpenetrating polymer networks and drug delivery.


Biomodics’ core technologies and services include; supercriticial fluid processing, functional surfaces and materials for drug delivery, biological nano-sensing and characterization.


Biomodics is actively developing the future medical devices for the health care sector. This focus includes proprietary technology within hybrid polymers and medical devices.


Biomodics has repeatedly been acknowledged in events such as the Eurecan European Venture Contest where an international jury selected Biomodics as the overall winner.


Biomodics started as a spinout from the large Danish technology company NKT in 2009. The company has built up a strong patent portfolio of new material technologies and applications based on CO2 technology.


Another focus area for the company is the development of innovative drug delivery solutions.


Biomodics specialises in processing using supercritical CO2 such as purification, extraction and sterilization.


Our mission


We believe that healthcare associated infections and pain can be almost eliminated. We want to end unnecessary illness and suffering of patients by bringing to market new and innovative medical devices that will help patients get better rather than make them suffer. Avoiding infections in hospitals saves lives and frees up resources.





You are always welcome to contact us for further information

a talk over the phone, or to schedule a personal meeting.


Biomodics ApS

Fjeldhammervej 15,

DK-2610 Rødovre



Phone: +45 61666619

Email: info@biomodics.com










Copyright ©2018 Biomodics, All Rights Reserved